Is Xefo Rapid (lornoxicam) a selective cyclooxygenase‑2 (COX‑2) inhibitor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, Xefo Rapid (lornoxicam) is NOT a selective COX-2 inhibitor

Lornoxicam is a nonselective NSAID that inhibits both COX-1 and COX-2 enzymes in a balanced manner. This distinguishes it from selective COX-2 inhibitors (coxibs) like celecoxib, rofecoxib, or etoricoxib 1.

Mechanism of Action

Lornoxicam demonstrates balanced inhibition of both COX-1 and COX-2 with nearly equal potency. Research shows it has an IC50 of 0.005 μM for COX-1 and 0.008 μM for COX-2 in intact human cells, making it one of the most potent balanced COX inhibitors tested 2. This equipotent inhibition of both isoforms places it firmly in the category of traditional nonselective NSAIDs 1.

Clinical Classification

According to consensus guidelines, NSAIDs are classified into two main categories 1:

  • Nonselective NSAIDs (nsNSAIDs): Reversibly inhibit both COX-1 and COX-2 activity
  • Coxibs (selective NSAIDs): Reversibly inhibit COX-2 more than COX-1 due to higher affinity for COX-2

Lornoxicam belongs to the first category as a nonselective NSAID.

Clinical Implications

Gastrointestinal Risk

Because lornoxicam inhibits COX-1 (which produces gastroprotective prostaglandins), it carries the typical GI risks associated with nonselective NSAIDs 1, 3. However, pooled data from 60 studies showed that lornoxicam had a reduced risk of GI adverse events compared to other NSAIDs (relative risk 0.78,95% CI: 0.64-0.96) 4, though GI events still occurred in 14% of patients versus 8% with placebo.

Cardiovascular Considerations

Unlike selective COX-2 inhibitors that preferentially reduce prostacyclin while sparing thromboxane production, lornoxicam's balanced COX inhibition theoretically provides a more favorable cardiovascular profile 5, 6. The cardiovascular risk with COX-2 selective agents is proportional to their degree of COX-2 selectivity 7, 5.

Appropriate Use

When prescribing lornoxicam, apply the same precautions as with other nonselective NSAIDs 8:

  • Consider GI prophylaxis with a proton pump inhibitor in high-risk patients (history of ulcers, age ≥75 years, concurrent aspirin use) 8, 9
  • Avoid in patients with chronic kidney disease stage IV-V, active peptic ulcer disease, or heart failure 8, 10
  • Monitor renal function, blood pressure, and cardiovascular status, especially in elderly patients 10
  • Use the lowest effective dose for the shortest duration necessary 7

Common Pitfall

Do not assume that lornoxicam has the same GI safety profile as selective COX-2 inhibitors when used alone. While it may have somewhat better GI tolerability than some other nonselective NSAIDs 4, it still requires the same risk mitigation strategies as traditional NSAIDs, particularly regarding gastroprotection in high-risk patients 8, 9.

References

Research

The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1999

Guideline

pharmacological management of persistent pain in older persons.

Journal of the American Geriatrics Society (JAGS), 2009

Guideline

nsaid prescribing precautions.

American family physician, 2009

Related Questions

When is celecoxib preferred over ibuprofen, and what are the dosing recommendations, contraindications, and safety considerations for each NSAID?
What COX‑2 inhibitors (e.g., celecoxib, etoricoxib) can be used in a patient without active gastrointestinal ulcer disease, significant cardiovascular disease, severe renal impairment, or aspirin‑sensitive asthma?
How do cyclooxygenase‑2 (COX‑2) inhibitors differ from ketorolac in mechanism of action, analgesic potency, safety profile, and recommended dosing?
For a typical adult without a history of gastrointestinal ulcer, cardiovascular disease, renal impairment, or NSAID hypersensitivity, which is more appropriate for short‑term relief of mild‑to‑moderate musculoskeletal pain: etodolac or ibuprofen?
Which of the following is a Cox-2 (Cyclooxygenase-2) selective Non-Steroidal Anti-Inflammatory Drug (NSAID)?
What is antidiuretic hormone (ADH)?
Which whey protein isolate available in Brazil and which multivitamin formulation are most appropriate for the patient?
How should exophthalmos be evaluated and managed?
In a patient with gastroenteritis who has a normal blood pressure of 130/80 mm Hg but a tachycardic pulse of 110 beats per minute, should IV rehydration be initiated?
What is the recommended therapeutic hypothermia protocol for hypoxic‑ischemic encephalopathy in term neonates and in adults after cardiac arrest?
What is the recommended therapeutic hypothermia protocol for a term infant with moderate-to-severe hypoxic‑ischemic encephalopathy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.